Arcus Biosciences Inc. (RCUS), a clinical-stage, global biopharmaceutical company designing combination therapies for cancer, expects to have six ongoing phase III trials for three distinct programs by the beginning of next year.
The investigational drugs in the pipeline include Domvanalimab, Zimberelimab, Casdatifan, Quemliclustat, Etrumadenant, AB598 and AB801.
Domvanalimab-Zimberelimab
A phase II, multi-arm, global study evaluating the safety and efficacy of various combinations of Domvanalimab and Zimberelimab in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma, dubbed EDGE-Gastric trial, is underway.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.